SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Dividend Growth Investing and chit chat.
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
Recommended by:
red cardinal
From: rnsmth11/2/2022 7:26:13 PM
1 Recommendation   of 2146
 
Many of us own JNJ. seekingalpha.com


J&J, Alkermes, AbbVie, others set to benefit from expanding schizophrenia drug market

Oct. 22, 2022 4:00 PM ET Johnson & Johnson (JNJ), ABBV, TEVA, ALKS OTSKF, OTSKY, KRTX, CERE, MDCLF, HLUBF, HLBBFBy: Jonathan Block, SA News Editor 8 Comments

Olivier Le Moal/iStock via Getty Images

An increase in the patient population combined with new therapies in development means that the schizophrenia drug market will soar to $13B in 2031 from $9B in 2021, according to consulting and analytical firm GlobalData.

And there are several pharma companies -- among then Johnson & Johnson (NYSE: JNJ), Alkermes (NASDAQ: ALKS), and AbbVie (NYSE: ABBV) -- that could be among the key beneficiaries.

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News